The remaining challenges of pneumococcal disease in adults

Ludwig E., Bonanni P., Rohde G., Sayiner A., Torres A.

Source: Eur Respir Rev 2012; 21: 57-65
Journal Issue: March 2012 - 21 (123)
Disease area: Respiratory infections

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 4.5
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Ludwig E., Bonanni P., Rohde G., Sayiner A., Torres A.. The remaining challenges of pneumococcal disease in adults. Eur Respir Rev 2012; 21: 57-65

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Impact of pneumococcal vaccination in children in the distribution of serotypes in bacteriemic pneumococcal pneumonia in adults
Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis  
Year: 2017

Aetiology of paediatric pneumonia after the introduction of pneumococcal conjugate vaccine
Source: Eur Respir J 2013; 42: 1595-1603
Year: 2013

Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects
Source: Eur Respir J 2005; 26: 1086-1091
Year: 2005

Influence of pneumococcal serotype group on outcome in adults with bacteraemic pneumonia
Source: Eur Respir J 2010; 36: 1073-1079
Year: 2010

Impact of introducing the 10-valent pneumococcal conjugate vaccine on childhood hospitalizations for bacterial pneumonia in Brazil
Source: Annual Congress 2013 –Paediatric respiratory epidemiology: bronchiolitis and asthma
Year: 2013

Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia
Source: Eur Respir J 2015; 45: 1632-1641
Year: 2015

Clinical effectiveness of pneumococcal vaccination against nonbacteremic pneumonia in people over 50 years
Source: Annual Congress 2008 - Community-acquired pneumonia: prognosis, complications and prevention
Year: 2008

Clinical presentations and serotypes causing invasive pneumococcal disease in adults vaccinated with the 23-valent polysaccharide pneumococcal vaccine (PPV23) in Spain. The ODIN study (2010-2013)
Source: International Congress 2014 – The epidemiology of respiratory infections and lung cancer
Year: 2014

Invasive pneumococcal disease (IPN) and pneumococcal vaccination in our setting
Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management
Year: 2015

Impaired response to 13-valent pneumococcal conjugate vaccine (PCV13) in children with recurrent respiratory infections and chronic cough.
Source: Virtual Congress 2021 – Paediatric respiratory infections: chronic infection, vaccination and lung function
Year: 2021

Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly
Source: Eur Respir J 2010; 36: 608-614
Year: 2010

A longitudinal analysis of pneumococcal vaccine serotypes in pneumonia patients in Germany
Source: Eur Respir J, 59 (2) 2102432; 10.1183/13993003.02432-2021
Year: 2022

Risk factors for respiratory failure in pneumococcal pneumonia: the importance of pneumococcal serotypes
Source: Eur Respir J 2014; 43: 545-553
Year: 2013

No preventive effects of 23-valent pneumococcal polysaccharide vaccine in patients with chronic renal failure
Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment
Year: 2016

Influenza vaccination is associated with reduced severity of community-acquired pneumonia
Source: Eur Respir J 2011; 37: 147-153
Year: 2011

Influenza and pneumococcal vaccination in patients with COPD
Source: Virtual Congress 2020 – Pharmacological management of COPD
Year: 2020

Should pneumococcal vaccines be used to prevent LRTI?
Source: Annual Congress 2009 - PG1 EU GRACE Network Full-day Course: vaccination and preventive measures for LRTIs in the community: what’s new?
Year: 2009

Effectiveness of a 23-valent pneumococcal polysaccharide vaccine and a 13-valent pneumococcal conjugate vaccine among the elderly with chronic respiratory diseases
Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit
Year: 2018